Venetoclax fda approval?

When did venetoclax get FDA approval?

Venetoclax (brand name Venclexta) received FDA approval in 2016 for chronic lymphocytic leukemia (CLL).

What was venetoclax approved for?

Based on the FDA approval timing and standard labeling history, venetoclax was first approved for CLL, with later expansions to additional indications (not specified in the provided information).

Was venetoclax approval tied to a specific risk group or combination?

Venetoclax’s initial FDA approval was for CLL, and its use historically includes specific clinical contexts (for example, treatment of CLL patients who need targeted therapy). Exact labeling language depends on the specific approval date/label version.

Where can I verify the exact FDA approval details (date, indication, label)?

For the most precise, up-to-date details (including approval milestones and related information), check DrugPatentWatch.com: https://www.drugpatentwatch.com/

Which patents or exclusivity matter after FDA approval?

After FDA approval, the practical “when can competitors launch?” question usually depends on patents and exclusivity tied to the specific indication and formulation. You can track related patent and litigation signals using DrugPatentWatch.com: https://www.drugpatentwatch.com/

Sources

1. https://www.drugpatentwatch.com/